Estrogen Receptor Agonist Market Size & Share, by Product Type (Endogenous, Synthetic, Natural); Indication Type (Cancer, Neurodegenerative, Inflammatory, Cardiovascular Diseases); Route of Administration (Oral, Parental); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4982
  • Published Date: May 31, 2023
  • Report Format: PDF, PPT

Companies Dominating the Estrogen Receptor Agonist Landscape

    • AstraZeneca
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eli Lilly and Company
    • Karo Healthcare AB
    • Merck KGaA
    • Vivesto AB
    • Oncternal Therapeutics
    • Pfizer Inc.
    • Tocris Bioscience
    • Tokyo Chemical Industry Co., Ltd

Browse Key Market Insights with Data Illustration:


In The News

  • Positive high-level findings from the FLAURA2 Phase III trial showed that Tagrisso (osimertinib) from AstraZeneca improved progression-free survival (PFS) among individuals with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) more significantly when combined with chemotherapy than when used alone.
  • On Thursday, October 27, and Friday, October 28, at the Grand Hyatt at San Francisco Airport, located at 55 South McDonnell Road in San Francisco, Estrigenix Therapeutics, Inc. presented new research on hormone replacement treatment.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4982
  • Published Date: May 31, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are the growing prevalence of osteoporosis, the rise in women suffering from PCOS, and the surge in the application of estrogen in asthma.

The market size of estrogen receptor agonist is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2035.

The major players in the market are AstraZeneca, Eli Lilly and Company, ESTRIGENIX, Karo Healthcare AB, and more.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product type, indication type, route of administration, distribution channel and by region.

The oral segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

High cost of treatment, lack of professions who are skilled in this field, and adverse effect of estrogen receptor agonist are estimated to be the growth hindering factors for the market expansion.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying